Angiostatin, a plasminogen fragment containing 3-4 N-terminal kringle domains, is a potent inhibitor of tumor-induced angiogenesis, but its mechanism of action is unclear.
INTRODUCTION
Angiogenesis, the outgrowth of new capillaries from preexisting vessels, is essential for wound healing, female reproduction, embryonic development, organ formation, tissue regeneration, and tissue remodeling ((1) and references therein).
Angiogenesis is a complex multistep process that includes endothelial proliferation, migration and differentiation, degradation of extracellular matrices, tube formation, and sprouting of new capillary branches. Several recent studies have shown that tumor growth and metastasis are angiogenesis-dependent (2) (3) (4) (5) . Tumors often overexpress several angiogenic stimulators, including members of the fibroblast growth factor (FGF) (6) and the vascular endothelial growth factor/vascular permeability factor families (7, 8) to induce neovascularization. A number of angiogenesis inhibitors (e.g., angiostatin and endostatin) have been identified and they are mostly fragments or cryptic domains of large protein molecules ((9) for review).
Angiostatin, a proteolytic fragment of plasminogen, contains either the first three or first four kringle domains of plasminogen and is a potent inhibitor of tumor-induced angiogenesis in animal models (2, 10) . Angiostatin has promising therapeutic potential and is now in clinical trials. Plasminogen is first converted to the two-chain serine protease plasmin by cleavage of a single Arg561-Val562 peptide bond by urokinase-type plasminogen activator, and plasmin serves as both the substrate and enzyme for the generation of angiostatin (11) . Several other mechanisms have been proposed for the generation of angiostatin from the plasminogen molecule ((12) and references therein).
The anti-angiogenic functions of plasminogen kringles have been extensively studied using recombinant plasminogen kringles and kringle fragments produced by elastolytic processing of native plasminogen. Smaller fragments of angiostatin display differential effects on suppression of endothelial cell growth (13) . Angiostatin has been reported to increase endothelial-cell apoptosis and the activity of focal adhesion kinase (14), and to 4 Recently, we have demonstrated that angiostatin binds to integrin αvβ3 and that αvβ3 may be a predominant receptor for angiostatin in bovine arterial endothelial (BAE) cells (17) . Integrin αvβ3 is a receptor for a wide variety of extracellular matrix ligands, including vitronectin, fibronectin, and fibrinogen. Endothelial cells exposed to growth factors, or undergoing angiogenesis in tumors, wounds, or inflammatory tissue, express high levels of αvβ3 ((18) and references therein). The expression of αvβ3 on activated endothelial cells suggests that this integrin may have an important function in angiogenesis as well as in developmental neovascularization. In fact, disruption of αvβ3 ligation with antibody (LM609) or peptide antagonists of αvβ3 disrupts blood vessel formation. These antagonists perturb the growth and/or maturation of new blood vessels without detectably influencing the pre-existing blood vessels. In tumor models, inhibition of blood vessels by αv integrin antagonists not only blocked tumor-associated angiogenesis but in some cases caused tumor regression (3). We hypothesized that angiostatin potentially perturbs the critical αvβ3 mediated signaling pathway in endothelial cells. Consistent with this idea, we have shown that angiostatin does not induce stress fiber formation on αvβ3 binding (17) .
Several previous reports suggest that plasmin, a serine protease and the parent molecule of angiostatin, transduces signaling (e.g., protein phosphorylation, Ca 2+ mobilization, and phospholipase C and protein kinase C activation) (19) (20) (21) (22) . Plasmin has also been reported to induce migration of human peripheral blood monocytes (23) . In this paper, we demonstrate that plasmin specifically binds to integrin αvβ3 through its kringle domains, like angiostatin. In addition, we found that plasmin induced migration of endothelial cells. This activity of plasmin required both an interaction with αvβ3 and the catalytic activity of plasmin. Angiostatin, anti-αvβ3 agents, and a serine protease inhibitor effectively blocked plasmin-induced cell migration. We propose that plasmin signaling is a potential target for angiostatin.
EXPERIMENTAL PROCEDURES
Materials. Human Glu-plasminogen, the native circulating form of the molecule, was isolated from fresh human plasma by affinity chromatography on Lys-Sepharose and molecular exclusion chromatography as described (24) . Elastase degradation products of plasminogen were prepared according to the method of Sottrup-Jensen et al. (25) and the characteristics of such preparations from our laboratory have been described previously Adhesion assays. Adhesion assays were performed as previously described (29) . Briefly, we coated wells of 96-well Immulon-2 microtiter plates (Dynatech Laboratories, Chantilly, VA) with 100 µl of PBS (10 mM phosphate buffer, 0.15 M NaCl, pH 7.4) containing substrates at a concentration of 50-500 nM and incubated for 1 h at 37°C. We Other Methods. We carried out flow cytometric analysis and stress fiber staining (17) as described.
RESULTS
Plasmin is a ligand for integrin αvβ3.
Since αvβ3 on endothelial cells binds to angiostatin, but not to plasminogen (17) , it is likely that proteolysis of plasminogen to angiostatin exposes the integrin-binding sites in the kringle domains. We tested whether proteolytic activation of plasminogen to plasmin similarly exposes the integrin binding sites. We found that plasmin supported adhesion of β3-CHO cells, but did not support adhesion of mock-transfected CHO cells (Fig. 1a) . While anti-αvβ3 mAb LM609 completely blocked adhesion of β3-CHO cells to plasmin, control anti-integrin α5 (KH72) did not (Fig. 1b) . RGD peptide completely blocked, but control RGE peptide did not block, adhesion of β3-CHO cells to plasmin, suggesting that αvβ3 binds to plasmin in an RGD-dependent manner, although the RGD sequence is not present in plasmin. This also indicates that the integrin-binding sites within the kringle domain of plasminogen are exposed by proteolytic activation of plasminogen to plasmin.
BAE cells constitutively express integrins αvβ3 and α9β1 on their surface, and both integrins bind to angiostatin (17) . BAE cells adhered to plasmin at a level higher than that of β3-CHO cells (Fig. 1a) . LM609 effectively blocked adhesion of BAE cells to plasmin (Fig. 1c) , but Y9A2 (anti-α9) had only a minimal effect, suggesting that αvβ3 may be a predominant receptor for plasmin on BAE cells.
The kringle domains of plasminogen have multiple Lys-binding sites (30) . We have shown that a Lys-analogue (ε-aminocaproic acid, EACA) completely blocked adhesion of BAE cells to angiostatin (17) . We found that EACA effectively blocked plasmin binding to αvβ3 (Fig. 1b and c) . Furthermore, a mAb against plasminogen kringles (mAb 51) blocked interaction between plasmin and these integrins (Fig. 1b and   c ). These results suggest that plasmin specifically binds to αvβ3 through the kringle domains as in the case of angiostatin.
We previously reported that angiostatin did not induce cell spreading or stress fiber formation (17) . In contrast to angiostatin, we found that plasmin induced cell spreading and stress fiber formation in β3-CHO and BAE cells (Fig. 2a-d Integrin-and the catalytic activity-dependence of plasmin-induced migration of endothelial cells, and the inhibitory effect of angiostatin (K1-3).
Migration of endothelial cells is critically involved in angiogenesis (1, 31) . It has been reported that plasmin is a potent chemo-attractant for human peripheral monocytes (23) . We studied whether plasmin induces cell migration in an integrin-dependent manner using a modified Boyden chamber assay. Notably, plasmin induced migration of β3-CHO and BAE cells in a dose-dependent manner (Fig. 3a and c) . Mock-transfected CHO cells migrated at a much lower rate. In contrast to plasmin, angiostatin or plasminogen did not induce migration of these cells ( Fig. 3b and d) . It has been reported that the angiogenic growth factor bFGF increases the expression levels and the activity of several integrins, including αvβ3 (32-34). Consistently, we found that bFGF significantly enhanced the plasmin-induced migration of β3-CHO and BAE cells ( Fig. 3b and d) .
We tested the effect of several antagonists to integrins and plasmin on plasmininduced cell migration. We found that LM609 effectively blocked plasmin-induced migration of β3-CHO and BAE cells, indicating that αvβ3 is critical for plasmin-induced migration. We found that integrin α9β1 is also involved in plasmin-induced migration of BAE cells (data not shown), and that combined LM609 and Y9A2 mAbs more effectively block plasmin-induced migration of BAE cells (Fig. 3d ) than LM609 alone.
Although both angiostatin and plasmin bind to integrin αvβ3 through their kringle domains, angiostatin did not induce cell migration. Thus we hypothesized that angiostatin may be an inhibitor of plasmin-induced cell migration. Notably, we found that soluble angiostatin effectively blocked plasmin-induced migration of β3-CHO and BAE cells inn the presence of bFGF ( Fig. 3b and d) .
Interestingly, aprotinin, a serine protease inhibitor, effectively blocked the migration of these cells on plasmin ( Fig. 3b and d) , suggesting that the catalytic activity of plasmin may be important for plasmin-induced cell migration. Taken together, these results suggest that plasmin-induced migration is dependent on the integrins and the 9 catalytic activity of plasmin, and that blocking plasmin-induced migration of endothelial cells may be a potential mechanism by which angiostatin can exert its effects.
The role of the kringle domains in plasmin-induced cell migration.
To study the role of kringle domains in integrin binding and cell migration, we tested the ability of mini-plasmin (which has only a single kringle domain, K5) to bind to αvβ3 and to induce migration of β3-CHO cells. When compared to plasmin, a much higher coating concentration of mini-plasmin was required for mini-plasmin to support adhesion of β3-CHO cells (Fig. 4a) , suggesting that mini-plasmin has a much lower affinity for αvβ3 than plasmin. The coating concentrations that provide half-maximal adhesion are 50-100 nM for plasmin and K1-3, and >400 nM for mini-plasmin (Fig. 4a) . Consistently, miniplasmin did not induce cell migration at the concentrations where plasmin induced cell migration (100 nM). However, mini-plasmin induced cell migration at higher concentrations (500-1000 nM) and reached a level several times higher than with plasmin (Fig. 4b) . These results suggest that a single kringle domain is able to bind to αvβ3 and is sufficient to support the signaling function of the catalytic domain of plasmin. It is likely that the number of the kringle domains per molecule may affect the level of the catalytic domain (which mediates signaling) on the cell surface.
10 DISCUSSION.
Previously, we have shown that angiostatin binds to integrin αvβ3, while plasminogen does not (17) . The present results establish that plasmin, like angiostatin, binds to integrin αvβ3 through the kringle domains as well. These results suggest that the integrin binding sites in the kringle domains are exposed by proteolytic activation of plasminogen to plasmin. It should be noted that the kringle domain of plasmin is still attached to the catalytic domain by inter-chain disulfide linkage. We have shown that plasmin induced spreading and stress fiber formation of β3-CHO and BAE cells. This is in sharp contrast to angiostatin, which did not induce spreading and stress fiber formation (17) . Furthermore, we have shown that plasmin induced migration of β3-CHO and BAE cells. Interestingly, plasmin-induced cell migration required integrin αvβ3 as well as the catalytic activity of plasmin. Importantly, we have shown that angiostatin effectively blocked plasmin-induced spreading, stress fiber formation, and migration of β3-CHO and BAE cells. The present findings suggest that blocking the plasmin signaling in endothelial cells may be a potential mechanism by which angiostatin exerts its effects (Fig. 5a ).
Several previous reports suggest that plasmin transduces signaling. Plasmin causes platelet aggregation and secretion associated with protein phosphorylation, Ca It is likely that plasmin binding to integrin αvβ3 may also prevent inactivation of plasmin. It has been reported that circulating abundant α 2 -antiplasmin rapidly inactivates free plasmin through binding to the kringle domain of plasmin ((38) for a review).
Binding of plasmin to integrins through the kringle domain may prevent inactivation of plasmin by occupying α 2 -antiplasmin binding sites. In addition, urokinase-type plasminogen activator and the urokinase receptor (CD87) are not expressed by quiescent endothelium, but are expressed in endothelium during angiogenesis ((39) for review).
Taken together, the increased expression and affinity of αvβ3, the increased plasmin activation on the cell surface, and the increased plasmin stability by binding to integrins may increase the cell-surface plasmin concentration, and may lead to plasmin-mediated PAR-1 activation and subsequent cell migration in activated endothelial cells (Fig. 5a ).
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We have demonstrated that angiostatin effectively blocked plasmin-induced spreading, stress fiber formation, and migration of BAE and β3-CHO cells. It is likely that angiostatin may compete with plasmin for binding to integrin αvβ3, since they share common integrin-binding sites, the kringle domains. We propose that angiostatin may block accumulation of plasmin on the cell surface and block subsequent signaling. It is possible that angiostatin may facilitate inactivation of plasmin by blocking plasmin binding to integrins.
We have also demonstrated that mini-plasmin (K5 + the catalytic domain)
induced migration of β3-CHO cells to a much greater extent than plasmin, although miniplasmin showed much weaker affinity for integrins and higher concentrations of miniplasmin were required in order to observe migration. These results can be well explained taking into account that plasmin has multiple (five), and mini-plasmin has only a single, integrin-binding site in K5. If a plasmin molecule binds to multiple integrins through the kringle domains, several integrin molecules on the cell surface potentially could bind to the kringle domains of plasmin. Thus αvβ3 would be saturated with plasmin and the concentration of catalytic domains on the cell surface may not increase as the plasmin concentration increases. In contrast, since mini-plasmin has only a single kringle domain, the catalytic domains would reach a level higher than with plasmin before all the integrins are saturated. We suspect that angiostatin (with multiple kringles/integrin binding sites) could effectively saturate αvβ3 on the cell surface without inducing signals, and block accumulation of plasmin on the cell surface (Fig. 5b) .
It has been established that anti-αvβ3 antibodies (e.g., LM609) and RGD peptide or related compounds block angiogenesis ((40,41) and references therein) and that serine protease inhibitors (e.g., antithrombin) (42) effectively block cancer proliferation. How these agents exert anti-angiogenic function is unclear. Interestingly, these inhibitors blocked plasmin-induced migration of endothelial cells in the present study. The present results suggest that plasmin-induced cell migration may be a potential target for these anti-angiogenic agents as well (Fig. 5a ). We tested the ability of plasmin to induce stress fiber formation in β3-CHO (2a) and BAE (2b) cells. Poly-L-lysine and fibronectin were used as controls. We also tested the effect of soluble angiostatin (fragment K1-3) on plasmin-induced stress fiber formation.
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We have previously reported that K1-3 does not induce stress fiber formation (17) . We first tested the ability of plasmin to induce migration of β3-CHO and BAE cells as a function of plasmin concentration (3a and 3c). We then tested the effect of bFGF and plasmin on plasmin-induced migration of β3-CHO and BAE cells (3b and 3d). Migration assays were performed using a modified Boyden chamber assay. Data are shown as means ± S.D. of three independent experiments. The data in 3b and 3d are shown as percent of the number of cells using plasmin without bFGF as 100. 
